Your browser doesn't support javascript.
loading
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Ross, Lisa L; Walker, A Sarah; Lou, Yu; Tenorio, Allan R; Gibb, Diana M; Double, Julia; Gilks, Charles; McCoig, Cynthia C; Munderi, Paula; Musoro, Godfrey; Kityo, Cissy M; Grosskurth, Heiner; Hakim, James; Mugyenyi, Peter N; Cutrell, Amy; Perger, Teodora; Shaefer, Mark S.
Afiliação
  • Ross LL; Medical Affairs, ViiV Healthcare, Research Triangle Park, NC, United States of America.
  • Walker AS; Medical Research Council Clinical Trials Unit, University College, London, United Kingdom.
  • Lou Y; Statistics, PAREXEL International, Durham, NC, United States of America.
  • Tenorio AR; Physicians Group, ViiV Healthcare, Research Triangle Park, NC, United States of America.
  • Gibb DM; Medical Research Council Clinical Trials Unit, University College, London, United Kingdom.
  • Double J; Safety and Medical Governance, GlaxoSmithKline, Stockley Park, United Kingdom.
  • Gilks C; School of Population Health, University of Queensland, Brisbane, Australia.
  • McCoig CC; Physicians Group, ViiV Healthcare, Tres Cantos, Spain.
  • Munderi P; HIV Care Research Programme, MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
  • Musoro G; Department of Medicine, University of Zimbabwe, Harare, Zimbabwe.
  • Kityo CM; HIV Clinical Trials Unit, Joint Clinical Research Centre, Kampala, Uganda.
  • Grosskurth H; HIV Care Research Programme, MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
  • Hakim J; Department of Medicine, University of Zimbabwe, Harare, Zimbabwe.
  • Mugyenyi PN; HIV Clinical Trials Unit, Joint Clinical Research Centre, Kampala, Uganda.
  • Cutrell A; Healthcare Statistics, ViiV Healthcare, Research Triangle Park, NC, United States of America.
  • Perger T; Safety and Pharmacovigilance, ViiV Healthcare, London, United Kingdom.
  • Shaefer MS; Medical Affairs, ViiV Healthcare, Research Triangle Park, NC, United States of America.
PLoS One ; 14(11): e0225199, 2019.
Article em En | MEDLINE | ID: mdl-31725787
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Lamivudina / Fármacos Anti-HIV / Creatinina Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Lamivudina / Fármacos Anti-HIV / Creatinina Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos